Polypeptide carrier protein
AssigneeNovartis AG
InventorsRino Rappuoli, Guido Grandi
Life of this patent
Estimating the term…
Abstract
The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.
Claims7
A carrier protein comprising at least five different CD4+ T cell epitopes, wherein the CD4+ T cell epitopes comprise epitopes from tetanus toxin, and epitopes from Plasmodium falciparum circumsporozite protein, hepatitis B surface antigen, hepatitis B nuclear core protein, influenza matrix protein, influenza haemagglutinin, diphtheria toxoid, diphtheria toxin mutant CRM197, group B Neisseria meningitidis outer membrane protein complex, pertussis toxin or heat shock protein 70.
Dependencies are inferred from the claim text.